<DOC>
	<DOC>NCT00364442</DOC>
	<brief_summary>A new formulation of Fluticasone propionate/Salmeterol comparing a lower dose of fluticasone propionate and salmeterol was compared with concurrent administration of fluticasone propionate and salmeterol. Administration occurred over 14 days and tolerability, PK (pharmacokinetic) and PD (pharmacodynamic) measurements were performed.</brief_summary>
	<brief_title>Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Documented history of mild or intermittent asthma Have PEF and FEV1&gt;80% predicted Not a smoker BMI of 19 29 Exclusion criteria: Have had a life threatening episode of asthma Have had a respiratory tract infection in the last four weeks Have other respiratory disease Have taken certain medications within restricted time periods</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>asthma</keyword>
</DOC>